Skip to main content

Table 1 Single nucleotide changes of TP53 mutations in therapy-related versus de novo myelodysplastic syndromes/acute myeloid leukemia (MDS/AML)

From: TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

Class

t-MN, n (%)

De novo MDS/AML, n (%)

C:Gā€‰>ā€‰A:T

5 (12.2)

1 (1.6)

C:Gā€‰>ā€‰G:C

3 (7.3)

6 (9.5)

C:Gā€‰>ā€‰T:A

18 (43.9)

35 (55.6)

T:Aā€‰>ā€‰A:T

4 (9.8)

3 (4.8)

T:Aā€‰>ā€‰C:G

9 (22.0)

12 (19.0)

T:Aā€‰>ā€‰G:C

2 (4.9)

6 (9.5)

Total

41 (100)

63 (100)